The Board of Directors, at its meeting on 9 February 2022 found that 100% of the performance conditions were achieved during the three years taken into consideration by the 17 April 2018 ACAs plan, namely 2019, 2020 and 2021. Accordingly, the beneficiaries who fulfil the conditions under the plan of 17 April 2022 and, in particular, that relating to the condition of presence in the Company, will receive 100% of the shares that were granted to them.
For information purposes, 30,000 shares were granted to the corporate officer, under the Plan of 17 April 2018. After application of the performance conditions, Mr Jean–Paul Agon will finally receive 30,000 shares.
| ACAs plan of 17 April 2018 | 2019 | 2020 | 2021 | Arithmetic average of performances for 2019,2020 and 2021 |
| 50% growth in like-for-like sales compared to a panel of competitors* | + 2.8 points (+8.0%/+5.2%) | + 4.0 points (-4.1%/-8.1%) | + 6.9 points (+16.1%/+9.2%) | + 4.6 points |
| 50% growth in the Group’s operating profit |
+12.71% (4,922.0/5,547.5) |
- 6.10% (5,547.5/5,209.0) |
+18.30% (5,209.0/6,160.3) |
+ 8.30 % |
*The Panel of competitors: Unilever, Procter & Gamble, Estée Lauder, Shiseido, Beiersdorf, Johnson & Johnson, Henkel, LVMH, Kao and Coty.
| ACAs plan of 18 April 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|
| 50% growth in like-for-like sales compared to a panel of competitors* | 50% growth in like-for-like sales compared to a panel of competitors *20204.0 points (-4.1%/-8.1%) |
50% growth in like-for-like sales compared to a panel of competitors *2021+ 6.9 points (+16.1%/+9.2%) |
50% growth in like-for-like sales compared to a panel of competitors *2022pending |
| 50% growth in the Group’s operating profit | 50% growth in the Group’s operating profit 2020- 6.10%(5,547.5/5,209.0) |
50% growth in the Group’s operating profit 2021+ 18.30%(5,209.0/6,160.3) |
50% growth in the Group’s operating profit 2022pending |
| ACAs plan of 14 October 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|
| 50% growth in like-for-like sales compared to a panel of competitors* | 50% growth in like-for-like sales compared to a panel of competitors *2021+ 6.9 points(+16.1%/+9.2%) |
50% growth in like-for-like sales compared to a panel of competitors *2022pending |
50% growth in like-for-like sales compared to a panel of competitors *2023pending |
| 50% growth in the Group’s operating profit | 50% growth in the Group’s operating profit 2021+ 18.30%(5,209.0/6,160.3) |
50% growth in the Group’s operating profit 2022pending |
50% growth in the Group’s operating profit 2023pending |
| ACAs plan of 07 October 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|
| 50% growth in like-for-like sales compared to a panel of competitors* | 50% growth in like-for-like sales compared to a panel of competitors *2022pending |
50% growth in like-for-like sales compared to a panel of competitors *2023pending |
50% growth in like-for-like sales compared to a panel of competitors *2024pending |
| 50% growth in the Group’s operating profit | 50% growth in the Group’s operating profit 2022pending |
50% growth in the Group’s operating profit 2023pending |
50% growth in the Group’s operating profit 2024pending |
* The panel consists of the following companies: Unilever, Procter & Gamble, Estée Lauder, Shiseido, Beiersdorf, Johnson & Johnson, Henkel, LVMH, Kao and Coty.
The authorisation given to the Board of Directors by the Annual General Meeting on 30 June 2020 to carry out free grants of shares to Group employees and certain executive corporate officers is set to expire in 2022. A new authorisation will be submitted to the Annual General Meeting on 21 April 2022.
The Board of Directors, at its meeting of 9 February 2022 and on the recommendation of the Human Resources and Remuneration Committee, decided to introduce new criteria to assess the extra-financial performance in addition to the financial performance within the long-term incentive plans, in order to align them with L’Oréal’s strategy in which economic and social performance go hand-in-hand.
These performance conditions will take into account:
See Resolution 19 presented in chapter 8 of this document.
